Citi Downgrades Synergy Pharmaceuticals (SGYP) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Synergy Pharmaceuticals (SGYP) and its 'Poop Troop' are Oversold - BTIG
April 7, 2017 1:57 PM EDTBTIG analyst Timothy Chiang weighed in on Synergy Pharmaceuticals (NASDAQ: SGYP) after yesterday's "Poop Troop" news and competitor downgrade. Chiang views shares as oversold, and not reflecting the value of its recently launched Trulance product.
Chiang sees visibility on Trulance continuing to increase,... More
